Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

edoxaban

Known as: Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide 
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with… Expand
Review
2019
Review
2019
Essentials We investigated direct oral anticoagulant (DOAC) use in venous thromboembolism and thrombophilia. A comprehensive… Expand
Review
2018
Review
2018
ABSTRACT The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinicians worldwide due to… Expand
  • table 1
  • figure 1
  • table 2
  • table 4
  • table 5
Highly Cited
2018
Highly Cited
2018
Background Low‐molecular‐weight heparin is the standard treatment for cancer‐associated venous thromboembolism. The role of… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the… Expand
  • table 2
  • table 3
  • table 5
  • table 6
Highly Cited
2016
Highly Cited
2016
BACKGROUND We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2014
Highly Cited
2014
Among 80 healthy persons who had received a single dose of edoxaban, the whole-blood clotting time was reduced significantly more… Expand
  • figure 1
Highly Cited
2013
Highly Cited
2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of… Expand
  • table 1
  • figure 1
Highly Cited
2013
Highly Cited
2013
BACKGROUND Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) study of a single ascending dose (SAD… Expand